Abstract
Background and Aims Previous studies on the effects of resveratrol on metabolic indicators reported contradictory findings, and these indicators have not been frequently studied in patients with type 2 diabetes. In this study, we aimed to examine the effects of resveratrol on metabolic indicators in a specific group of people with type 2 diabetes using the most recent literature. Methods We used RevMan 5.4 and Stata 14.0 software to identify randomized controlled studies on the impact of resveratrol on metabolic indicators in patients with type 2 diabetes using relevant search terms and keywords such as “resveratrol” and “type 2 diabetes” in the China National Knowledge Infrastructure, PubMed, Cochrane, and Embase. Data were expressed as the weighted mean difference (WMD) and 95% confidence interval (CI). Results This meta-analysis included 19 studies involving 1151 patients with type 2 diabetes, including 584 patients treated with resveratrol and 567 patients who received placebo. Compared with the control data, large doses of resveratrol (≥1000 mg) reduced fasting blood glucose levels (WMD: −18.76 mg/dL, 95% CI: −23.43, −14.09; P < 0.00001). Additionally, resveratrol reduced systolic blood pressure (WMD: −7.97 mmHg, 95% CI: −10.63, −5.31; P < 0.00001) and diastolic blood pressure (WMD: −3.55 mmHg, 95% CI: −5.18, −1.93; P < 0.00001) in patients with type 2 diabetes but did not improve waist circumference (WMD: 0.05 cm, 95% CI: −1.77, 1.88; P=0.95), triglyceride levels (WMD: −4.49 mg/dL, 95% CI: −24.23, 15.25; P=0.66), or high-density lipoprotein cholesterol levels (WMD: −1.05 mg/dL, 95% CI: −2.44, 0.33; P=0.14) in patients with type 2 diabetes. Conclusion This systematic review and meta-analysis updated the most recent literature and provided new evidence, proving that resveratrol treatment can reduce systolic blood pressure and diastolic blood pressure. High-dose resveratrol can reduce fasting blood glucose in patients with type 2 diabetes, although it has no effect on waist circumference, triglyceride, and high-density lipoprotein cholesterol.
Highlights
With recent changes in lifestyle such as diets high in sugar and fat and a lack of exercise, the prevalence of diabetes has gradually increased [1]
We evaluated the effects of resveratrol supplementation compared to placebo in the treatment and prevention of type 2 diabetes. e included patients with type 2 diabetes met the diagnostic criteria for diabetes published by WHO in 1999 [18], including diabetes symptoms plus one of the following three diagnostic criteria: random blood glucose ≥ 11.1 mmol/L (200 mg/dL); fasting blood sugar (FBG; fasting refers to a period of at least 8 h without consuming calories) ≥ 7.0 mmol/L (126 mg/dL); and 2-hour blood glucose ≥11.1 mmol/L (200 mg/dL) after glucose loading
Study Characteristics. e basic features of the studies were as follows: first author’s name, year of publication, study site, patient age, course of disease, study sample size, resveratrol treatment dosage and intervention time, control group medication, and study design method. e eligible studies included seven studies conducted in Iran [19,20,21,22,23,24,25], three studies reported from China [26,27,28], two studies reported from India [29, 30], and one study each performed in Australia [31], Egypt [32], Netherlands [33], Singapore [34], Japan [35], Spain [36], and Italy [37]. e age of the patients in the studies ranged from 40.3 to 75 years, the resveratrol dosage ranged from 8.1 to 3000 mg/day, and the observation time spanned from 1.5 weeks to 12 months (Table 1)
Summary
With recent changes in lifestyle such as diets high in sugar and fat and a lack of exercise, the prevalence of diabetes has gradually increased [1]. We aimed to examine the effects of resveratrol on metabolic indicators in a specific group of people with type 2 diabetes using the most recent literature. Resveratrol reduced systolic blood pressure (WMD: −7.97 mmHg, 95% CI: −10.63, −5.31; P < 0.00001) and diastolic blood pressure (WMD: −3.55 mmHg, 95% CI: −5.18, −1.93; P < 0.00001) in patients with type 2 diabetes but did not improve waist circumference (WMD: 0.05 cm, 95% CI: −1.77, 1.88; P 0.95), triglyceride levels (WMD: −4.49 mg/dL, 95% CI: −24.23, 15.25; P 0.66), or high-density lipoprotein cholesterol levels (WMD: −1.05 mg/dL, 95% CI: −2.44, 0.33; P 0.14) in patients with type 2 diabetes. Highdose resveratrol can reduce fasting blood glucose in patients with type 2 diabetes, it has no effect on waist circumference, triglyceride, and high-density lipoprotein cholesterol
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
